Description
Book SynopsisThis book covers a comprehensive update on acute and chronic leukemia. In 54 chapters, authors introduce research progress and clinical trials of acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APL), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and chronic myeloid leukemia (CML). The last decade has seen the integration of genetic and clinical information to determine the prognosis and treatment strategies.
This book provides practitioners, researchers and graduate students of Hematology and Hematopathology a comprehensive update on the pathobiology, genomics, classification, diagnosis, monitoring, prognostication and therapy of both acute and chronic leukemias.
Table of ContentsChapter 1 Basic haematopoiesis and leukemia stem cells
Chapter 2 Modern classification of acute and chronic leukemias: integrating biology, clinicopathologic features and genomics
Chapter 3 Molecular techniques in the diagnosis and monitoring of acute and chronic leukemias
Chapter 4 Flow cytometric techniques in the diagnosis and monitoring of acute leukemias
Chapter 5 Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia
Chapter 6 Frontline management of acute myeloid leukaemia eligible for intensive chemotherapy
Chapter 7 Frontline management of elderly acute myeloid leukemia ineligible for intensive treatment
Chapter 8 Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia
Chapter 9 Management of relapsed or refractory AML
Chapter 10 The Role of BCL-2 / MCL-1 targeting in Acute Myeloid Leukemia
Chapter 11 Role of IDH1/IDH2 inhibitors in AML
Chapter 12 Next-generation FLT3 inhibitors for the treatment of FLT3-positive AML
Chapter 13 Allogeneic hematopoietic stem cell transplantation for AML
Chapter 14 Maintenance therapy following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
Chapter 15 Immunotherapeutic targeting of AML
Chapter 16 In the pipeline – Emerging therapy for acute myeloid leukaemia
Chapter 17 Frontline management of acute promyelocytic leukemia
Chapter 18 Management of relapsed acute promyelocyticleukemia and the role of hematopoietic stem cell transplantation
Chapter 19 Genomic Landscape of Acute Lymphoblastic Leukaemia (ALL) – Insights to Leukaemogenesis, Prognostications and Treatment
Chapter 20 Management of adolescent and young adults with Acute Lymphoblastic Leukaemia
Chapter 21 Management of older patients with acute lymphoblastic leukemia
Chapter 22 Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia
Chapter 23 Management of Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (Ph-like ALL)
Chapter 24 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia
Chapter 25 Immunotherapy for ALL
Chapter 26 In the Pipeline - Emerging therapy for ALL
Chapter 27 Inherited/genetic predisposition to MDS and AML
Chapter 28 Clonal hematopoiesis and its functional implications in MDS/AML
Chapter 29 Therapy-related MDS/AML and the role of environmental factors
Chapter 30 Prognostic indicators in MDS and CMML
Chapter 31 Treatment algorithm of myelodysplastic syndromes
Chapter 32 Treatment algorithm of CMML and other uncommon MDS/MPN subtypes
Chapter 33 Novel strategies to manage cytopenia in low-risk MDS
Chapter 34 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: when and how?
Chapter 35 In the Pipeline - Emerging therapy for MDS and MDS/MPN
Chapter 36 Molecular landscape and personalized prognostic prediction of MPNs
Chapter 37 Treatment algorithm of polycythemia Vera
Chapter 38 Treatment algorithm of essential thrombocythemia
Chapter 39 Prognostic models for primary and secondary myelofibrosis
Chapter 40 Treatment algorithm for primary and secondary myelofibrosis
Chapter 41 Diagnosis and management of prefibrotic primary myelofibrosis (pre-PMF)
Chapter 42 Interferons In myeloproliferative neoplasms
Chapter 43 JAK inhibitors for the management of myeloproliferative neoplasms
Chapter 44 Allogeneic hematopoietic stem cell transplantation for myelofibrosis – when and how?
Chapter 45 Thrombosis and myeloproliferative neoplasms
Chapter 46 Eosinophilic disorders and systemic mastocytosis
Chapter 47 In the Pipeline - Emerging therapy for classical Ph-negative MPNs
Chapter 48 "Current guidelines and treatment algorithm of
chronic myeloid leukaemia"
Chapter 49 Treatment-free remission in chronic myeloid leukemia
Chapter 50 Treatment options in CML resistant or intolerant to second-generation tyrosine kinase inhibitors
Chapter 51 Allogeneic hematopoietic cell transplantation in CML: when and how?
Chapter 52 In the Pipeline - Emerging therapy for CML
